arrow
K

Kazuma Kishi

Toranomon Hospital
H指数:34
被引数:8,243

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plasma metabolomic profiling to predict durable response and survival with afatinib in EGFR-mutated non-small cell lung cancer: A prospective, multicenter, observational biomarker study

血浆代谢组学分析预测EGFR突变非小细胞肺癌患者接受阿法替尼治疗后的持久缓解和生存:一项前瞻性、多中心、观察性生物标志物研究

2026-11-030
PRE
Differences in chest HRCT findings in relation to ANCA subtypes in ANCA-associated vasculitis

ANCA相关性血管炎中不同ANCA亚型与胸部高分辨率CT检查结果的差异

2026-05-010
PRE
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial

度鲁妥单抗、卡铂和依托泊苷用于治疗初治广泛期小细胞肺癌且体力状况较差的患者(NEJ045A):一项单臂Ⅱ期试验

2025-09-280
PRE
Plasma cell-free DNA methylation profile before afatinib treatment is associated with progression-free and overall survival of patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer

afatinib治疗前的血浆游离DNA甲基化谱与表皮生长因子受体基因突变阳性非小细胞肺癌患者的无进展生存期和总生存期相关

2025-04-250
OA
Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy
2024-05-031
OAAI
LIGHT-NING 2nd interim analysis: Early safety of 1L nivolumab plus ipilimumab plus /- chemotherapy for NSCLC in Japan
2023-11-011
OA
Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study
2023-06-051
OAAI